Anji Biotech

Strategic Cooperation

Why Partner With Us?

Nanjing Anji Biotech has been deeply engaged in innovative peptide drug R&D for more than 20 years. Relying on two core platforms - a globally leading high-throughput endogenous micropeptide novel-target discovery technology and China's exclusive fifth-generation structure-targeted peptide intelligent design technology (STP-CADD) - the company focuses on major unmet clinical needs such as oncology, fibrosis, autoimmune diseases, fundus diseases and pain, building an open cooperation system spanning multiple technologies, pipelines and models. Adhering to the philosophy of technological openness, industrial collaboration and shared value creation, Anji Biotech offers diversified cooperation models to domestic and international pharmaceutical companies, research institutions and industrial platforms.

  • Backed by its two exclusive core technology platforms, the company conducts long-term, in-depth industrial strategic cooperation and joint platform development. With its globally leading endogenous micropeptide discovery technology, it has built a reserve of 25 novel functional micropeptides and a vast pool of first-in-class (FIC) original targets; leveraging China's exclusive STP-CADD intelligent design technology, it can rapidly produce nM-affinity targeting warheads suitable for R&D across all categories of PXC conjugated drugs.

Partners discussing R&D projects around a table